Skip to content
value.today

Ventyx Biosciences, Inc.

Total raised
$192 M
3 rounds on record
Latest round
$27 M
Sep 2024
First round on record
Feb 2021
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Ventyx Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2024$27 MNo. 3$10 to $50 million

Ventyx Biosciences, Inc.: Raise no. 3, Sep 2024

Investors in this round

1 investor had bought by the notice of Sep 30, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Ventyx Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$27 M of $27 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Nuss · Executive Officer
  • Mark S. Forman · Executive Officer
  • Matthew Moore · Executive Officer
  • Raju Mohan · Executive Officer, Director
  • Allison S. Hulme · Director
  • Onaiza S. Cadoret-Manier · Director
  • Sheila S. Gujrathi · Director
  • Somasundaram Subramaniam · Director
  • William S. White · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Raju Mohan, Chief Executive Officer. Newest notice filed Sep 30, 2024. Read the notice at the SEC.

equitySEC
Sep 2021$51 MNo. 2$50 to $250 million

Ventyx Biosciences, Inc.: Raise no. 2, Sep 2021

Investors in this round

17 investors had bought by the notice of Sep 20, 2021: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Ventyx Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$51 M of $51 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher W. Krueger · Executive Officer
  • Martin W. Auster · Executive Officer
  • Raju W. Mohan · Executive Officer, Director
  • Aaron W. Royston · Director
  • Jigar W. Choksey · Director
  • Richard W. Gaster · Director
  • Sheila W. Gujrathi · Director
  • Somasundaram W. Subramaniam · Director
  • William W. White · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher W. Krueger, Chief Business Officer. Newest notice filed Sep 20, 2021. Read the notice at the SEC.

equitySEC
Feb 2021$114 MNo. 1$50 to $250 million

Ventyx Biosciences, Inc.: Raise no. 1, Feb 2021

Investors in this round

24 investors had bought by the notice of Jul 16, 2021: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Ventyx Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$114 M of $114 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher W. Krueger · Executive Officer
  • Martin W. Auster · Executive Officer
  • Raju W. Mohan · Executive Officer, Director
  • Aaron W. Royston · Director
  • Jigar W. Choksey · Director
  • Richard W. Gaster · Director
  • Sheila W. Gujrathi · Director
  • Somasundaram W. Subramaniam · Director
  • William W. White · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher W. Krueger, Chief Business Officer. Newest notice filed Jul 16, 2021 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Ventyx Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2024).

    SEC Form D · Sep 2024

  • The industry group it chose in its notices: Other.

    SEC Form D · Sep 2024

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in Ventyx Biosciences, Inc.
InvestorKindAmountRoundRoleSource
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Private Healthcare Fund III LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
NSV Investments I, L.P.Fund or asset managernot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
NSV Partners III GP LLCFund or asset managernot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
NSV Partners III LPFund or asset managernot statednot statedHeld Series A and A-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Sheila GujrathiPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2021)SEC Form 3
venBio Global Strategic Fund III, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Venbio Global Strategic GP III, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Venbio Global Strategic GP III, LTDCompanynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ventyx Biosciences, Inc.
NameRoleNamed in
John NussExecutive officerSep 2024
Mark S. FormanExecutive officerSep 2024
Matthew MooreExecutive officerSep 2024
Raju MohanExecutive officerSep 2024
Christopher W. KruegerExecutive officerSep 2021
Martin W. AusterExecutive officerSep 2021
Raju W. MohanExecutive officerSep 2021
Allison S. HulmeDirectorSep 2024
Onaiza S. Cadoret-ManierDirectorSep 2024
Raju MohanDirectorSep 2024
Sheila S. GujrathiDirectorSep 2024
Somasundaram SubramaniamDirectorSep 2024
William S. WhiteDirectorSep 2024
Aaron W. RoystonDirectorSep 2021
Jigar W. ChokseyDirectorSep 2021
Raju W. MohanDirectorSep 2021
Richard W. GasterDirectorSep 2021
Sheila W. GujrathiDirectorSep 2021
Somasundaram W. SubramaniamDirectorSep 2021
William W. WhiteDirectorSep 2021